WOODBRIDGE, Ontario,
August 19, 2014 /PRNewswire/ --
Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO),
("Pivotal" or the "Company"), a specialty pharmaceutical company
with a focus on Omega-3 therapies for cardiovascular disease
("CVD") and overall health, announced today that an article
entitled, "Redox-sensitive induction of Src/PI3-kinase/Akt
and MAPKs pathways activate eNOS in response to EPA:DHA
6:1," authored by Faraj Zgheel, Mahmoud Alhosin,
Sherzad Rashid, Mélanie Burban,
Cyril Auger and Valérie B.
Schini-Kerthhas been published in the current issue of the
scientific journal PLOS ONE and is available at
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0105102.
The findings of Zgheel et al. demonstrate that the sustained
endothelial vasodilatory effect of Omega-3 formulations are EPA:DHA
ratio and purity dependent and involve predominantly the
endothelial nitric oxide synthase derived nitric oxide
formation.
The Pivotal 6:1 EPA:DHA formulation of
VASCAZEN® was shown to cause the most
pronounced sustained vasodilatory effect when compared to a 1:1
EPA:DHA, pure EPA or pure DHA. The study published by the
researchers of the University of Strasbourg, France, is the first to
demonstrate that the biological activity of Omega-3 formulations is
not linked to either the ratio or the purity alone but depends on
the interplay of the components of each respective formulation.
"The significance of these results emphasizes not only the
superior sustained endothelial vasodilatory profile of Pivotal's
VASCAZEN®, but also points to its
beneficial effects in Omega-3 deficient individuals," said Dr.
George Jackowski, Chief Scientific
Officer. "We are very excited that the
VASCAZEN® formulation was superior to the
other existing commercial products in the marketplace in terms of
sustained coronary vasodilation (i.e. increase of blood flow) which
is important for patients with Coronary Heart Disease who have
compromised coronary vessels."
About PLOS ONE
PLOS ONE publishes primary research from all areas of
science and employs a combination of peer review and
post-publication rating and commenting, to maximize the impact of
every report it publishes. We are published by the Public Library
of Science (PLOS), the open-access publisher whose goal is to make
the world's scientific and medical literature a public resource.
All works published in PLOS ONE are Open Access.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF;
CSE:PVO), specialty pharmaceutical company with a focus on
cardiovascular disease and overall health. Pivotal Therapeutics'
lead product VASCAZEN® is a prescription
only medical food formulated to meet the dietary Omega-3 deficient
needs of patients with cardiovascular disease through elevating
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular
complications. OMAZEN® is a pharmaceutical
grade Omega-3 providing over 90% pure Omega-3 in each capsule for
the maintenance of good health. OMAZEN® is
a patented product available for sale and distribution in
Canada.
About VASCAZEN®
VASCAZEN® is currently available in the
U.S. as a prescription only medical food specifically formulated
for the dietary management of an Omega-3 deficiency in
cardiovascular patients. VASCAZEN® is a
>90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign
patents.
VASCAZEN® has been clinically shown to
correct an Omega-3 deficiency within eight weeks of treatment with
positive concomitant effects on the lipid profiles, mainly a 48%
reduction of triglycerides and an increase of HDL without negative
impact on the LDL-C lipid profile.
VASCAZEN®'s results were achieved with a
dose of 3 grams of EPA and DHA per day of a prescription grade,
high purity, uniquely formulated Omega-3.
Disclosure Notice
The information contained in this document is as of
August 19, 2014. This press release
contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as
"will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause
actual results to differ materially from those in forward looking
statements include the following: Pivotal's inability to obtain
additional financing on acceptable terms; growth in costs and
expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result
of new information or future events or developments. The CSE has
not reviewed and does not accept responsibility for the adequacy or
accuracy of this information.
For further information:
Company Contacts:
Kristine DiMatteo
Communications and Public Relations Manager
Phone: +1-905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us
Investor & Media Contact:
Stephen Kilmer
President, Kilmer Lucas Inc.
Phone: +1-647-872-4849
E-Mail: stephen@kilmerlucas.com